ClinicalTrials.gg
Not yet recruitingNCT06463769Updated Apr 29, 2026

Impact of Diet on the Microbiome-Immune-Brain Axis in Parkinson's Disease

An interventional study of 8 week predominantly plant-based New Nordic LPF-diet program and maintenance of the predominantly plant-based New Nordic LPF-diet in Parkinson Disease, sponsored by University of Kiel. Not yet recruiting at 2 sites in Germany. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of Kiel · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 264 studies in Parkinson Disease with a site in Germany — 41 open to participants now, 53 under way, 2 of them phase 3. Parkinson Disease · Germany.

Planned enrollment
119th of 198
75 · median 106
Started
2026
with 7 others
No phase
50 of 264
13 open now
Primary completion
2027-12
later than 31 of 52 live
Registered
233rd of 264
by date

Among the 264 studies in Parkinson Disease with a site in Germany, this one is the 119th largest by planned enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2026, is one of 50 with no phase, reaches primary completion later than 31 of the 52 other live ones, and was the 233rd registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

41 of the 264 studies in Parkinson Disease with a site in Germany are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies in Parkinson Disease with a site in Germany, or all of them as a file.
02

Study summary

Habitual adherence to a predominantly plant-based diet, rich in low-processed food (LPF) has been associated with a reduced risk for development and slower progression of Parkinson's Disease (PD). This could be due to neuroprotective effects by modulation of the gut microbiota and decreased neuronal and metabolic inflammation. So far, the effect of a predominantly plant-based LPF-diet on the microbiome-immune-brain axis in patients with PD remains unknown. In addition, the influence of dietetic measures on the gut microbiome is variable and may depend on (long-term) adherence as well as on PD-specific factors and lifestyle.

The investigators hypothesize that compared to an average German diet, the predominantly plant-based New Nordic LPF-diet, as a culturally adapted diet, which is rich in fermentable fiber and phytochemicals, will have beneficial effects on the gut microbiome of patients with PD by increasing the abundance of short-chain fatty acid (SCFA)-producing bacteria (primary outcome) and will improve gut motility, metabolic resilience, and inflammation (secondary outcomes). Furthermore, the investigators postulate that a patient-centered dietary intervention program, including a multifaceted patient education and supported by a web-application, will lead to high adherence as a key determinant of long-term changes in the gut microbiome. This dietary intervention will be accepted by patients as a low-threshold treatment that balances personal benefits, therapeutic barriers and ethical concerns of early risk disclosure in PD.

Read the detailed description

In a pilot-intervention study, our project will:

  • develop a practical, low-threshold diet intervention for patients with prodromal and clinical PD. Adherence will be promoted (i) by a patient-oriented approach, (ii) by implementation of the predominantly plant-based New Nordic LPF-diet that is scientifically-based, culturally adapted, sustainable and culinary and (iii) by an innovative web-application.
  • investigate the acute effects of the predominantly plant-based New Nordic LPF -diet on the microbiome (abundance of SCFA-producing bacteria), gastrointestinal motility, inflammation as well as metabolic and Parkinson-specific clinical outcomes in individuals with prodromal and clinical PD.
  • investigate potential determinants of long-term changes in the gut microbiome (e.g. dietary adherence, gastrointestinal motility, meal timing and frequency), and factors associated with a high adherence (e.g. acceptance of diet as therapeutic intervention in the prodromal phase, health-related quality of life).

The patient-centered intervention program will be tailored to individual needs and preferences of individuals with prodromal and clinical PD. It will be designed to impart knowledge (e.g. on sustainability and health effects) and food literacy (e.g. food merchandize and culinary skills) in group meetings and culinary medicine workshops. Recipe suggestions and shopping guides will consider individual abilities and needs and a web-application is used for information, increasing self-efficacy, motivation, and monitoring. To ensure an easy integration of the diet into everyday life, partners will be included in the program, if applicable. Moreover, cultural preferences as well as financial resources will be considered. Regular feedback using statistics on nutrient intake and overall progress will be implemented to encourage adherence.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • New Nordic Diet
  • Parkinson's Disease
  • Microbiome-Immune-Brain axis
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with probable prodromal PD (according to predefined criteria)
  • patients with clinical PD with slight to moderate disease severity (Hoehn \& Yahr 1-2.5)
  • habitual Western Diet (≥30% of energy intake from ultra-processed food)

Exclusion criteria

Exclusion Criteria:

  • current adherence to a plant-based diet
  • food allergies or intolerances
  • significant diseases of the gastrointestinal system (e.g. celiac disease) or central nervous system, diabetes mellitus
  • underweight ( \<18.5 kg/m2)
  • active smoking
  • expected changes in medication or antibiotic treatment during the intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Patients with prodromal PD on New Nordic LPF-diet (intervention)

    Patients with prodromal PD will take part in an 8-week patient-centered intervention program on a predominantly plant-based New Nordic LPF-Diet.

    Behavioral: 8 week predominantly plant-based New Nordic LPF-diet program · Behavioral: maintenance of the predominantly plant-based New Nordic LPF-diet

  • Experimental
    Patients with clinical PD on New Nordic LPF-diet (intervention)

    Patients with clinical PD will take part in an 8-week patient-centered intervention program on a predominantly plant-based New Nordic LPF-Diet. Patients with clinical PD will be randomized to intervention or control group.

    Behavioral: 8 week predominantly plant-based New Nordic LPF-diet program · Behavioral: maintenance of the predominantly plant-based New Nordic LPF-diet

  • No intervention
    Patients with clinical PD receiving standard of care (control)

    Patients with clinical PD will receive standard of care information on a healthy diet and serve as control. Patients with clinical PD will be randomized to intervention or control group.

Interventions

  • Behavioral8 week predominantly plant-based New Nordic LPF-diet program

    An 8-week patient-centered dietary intervention program will be implemented to maintain a predominantly plant-based New Nordic LPF-Diet.

  • Behavioralmaintenance of the predominantly plant-based New Nordic LPF-diet

    Follow-up of long-term adherence to the diet at one and six months after completion of the intervention program.

06

What researchers measure

Primary outcomes

  1. abundance of key SCFA-producing gut bacteria

    analysis of stool samples

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

Secondary outcomes

  1. systemic inflammation markers

    hsCRP and IL-6 in serum

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  2. metabolic resilience

    modeling of one parameter (metabolic resilience) including information on postprandial glucose, insulin, triglycerides and NEFA following a mixed meal tolerance test

    Time frame: pre vs. post intervention (8 weeks)

  3. gastrointestinal peptide-hormones

    ghrelin, GLP-1, PYY

    Time frame: pre vs. post intervention (8 weeks)

  4. energy balance

    changes in body weight

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  5. energy partitioning

    changes in body composition

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

Other outcomes

  1. clinical motor symptoms

    clinical examination

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  2. clinical non-motor symptoms

    clinical examination

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  3. gastric emptying

    13C-breath test

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  4. gastrointestinal transit time

    using a test meal with food colouring and the time to colour appearance in stool

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  5. gut motility

    functional visceral MRI

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  6. dietary adherence via serum markers

    serum carotinoid and Trimethylamine oxid-levels will be combined and tertiles will be formed

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  7. dietary adherence via healthy Nordic food Index

    healthy Nordic food Index using data from a food frequency questionnaire

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  8. food literacy effectiveness

    self-perceived food literacy scale (questionnaire)

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  9. patient acceptance

    Parkinson's Disease Questionnaire (PDQ-39)

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

  10. patient quality of life

    Ways of Coping Questionnaire (WCQ)

    Time frame: pre vs. post intervention (8 weeks) + pre intervention vs. follow-up 6 months after completion of intervention

07

Study locations

2 sites
08

References and documents

Publications

  • Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, Hertzberg V, Auvinen P, Tansey MG, Scheperjans F. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease. Mol Neurodegener. 2021 Feb 8;16(1):6. doi: 10.1186/s13024-021-00427-6. PubMed 33557896 ↗
  • Solch RJ, Aigbogun JO, Voyiadjis AG, Talkington GM, Darensbourg RM, O'Connell S, Pickett KM, Perez SR, Maraganore DM. Mediterranean diet adherence, gut microbiota, and Alzheimer's or Parkinson's disease risk: A systematic review. J Neurol Sci. 2022 Mar 15;434:120166. doi: 10.1016/j.jns.2022.120166. Epub 2022 Jan 26. PubMed 35144237 ↗
  • Maraki MI, Yannakoulia M, Stamelou M, Stefanis L, Xiromerisiou G, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, Anastasiou CA, Simopoulou E, Scarmeas N. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. Mov Disord. 2019 Jan;34(1):48-57. doi: 10.1002/mds.27489. Epub 2018 Oct 10. PubMed 30306634 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 19 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 18, 2024
StartEst.
May 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jul 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06463769
Lead sponsor
University of Kiel
Responsible party
Prof. Dr. Dr. Anja Bosy-Westphal (Head of the Department of Human Nutrition, Kiel University, University of Kiel) — Principal investigator
First posted
Jun 18, 2024
Start date
May 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Anja Bosy-Westphal, PhD, MD
Contact
abosyw@nutrition.uni-kiel.de
+494318805674
Eva Schäffer, MD
Contact
eva.schaeffer@uksh.de
+49431 500 23800
Anja Bosy-Westphal, PhD, MD
principal investigator · University of Kiel
Eva Schäffer, MD
principal investigator · Kiel University, University Hospital Schleswig-Holstein

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion